Clinical trials: Renal Transplant Recipient
Liver Transplantation
Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients
This trial evaluated the efficacy and safety of Everolimus in combination with tacrolimus versus a standard immunosuppressive regimen concerning kidney function in liver transplant recipients.
- Trial name
- HEPHAISTOS (NCT01551212)
- Testing
- Everolimus, Tacrolimus, Corticosteroids
- Where
- 15 sites in Germany
- Volunteers
- 339 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplantation
Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients
The purpose of this study is to evaluate the safety and tolerability of RAD001 (Certican) administered to pediatric renal transplant recipients, and to provide additional safety data.
- Trial name
- NCT00098241
- Testing
- Certican
- Where
- 2 sites in United States, Belgium
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplant; Complications
Home-based Exercise in Renal Transplant Recipients
Although patients who have received a kidney transplant have better health than patients on dialysis, heart problems are still the commonest cause of death for kidney transplant recipients.
- Trial name
- ECSERT (NCT04123951)
- Testing
- Home-based Exercise
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Leicester
Cardiac Surgery, Cardiopulmonary Bypass
REnal TRansplant Outcomes After CARdiac Surgery (RETROCAR)
In this retrospective study, the authors assess long term renal outcome in renal transplant recipients after cardiac surgery with cardiopulmonary bypass, and research factors associated with poor long term renal outcome.
- Conditions
- Cardiac Surgery, Cardiopulmonary Bypass, Renal Transplant Recipient
- Trial name
- RETROCAR (NCT04979754)
- Testing
- standard of care
- Where
- France
- Volunteers
- 93 people
- Sponsor
- University Hospital, Bordeaux
Chronic Renal Failure
Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients
The primary objective of this trial is to show non-inferiority of a CNI-free regimen with respect to the renal function at Month 9 post Tx assessed by glomerular filtration rate - Nankivell method - as compared to the standard…
- Trial name
- NCT00965094
- Testing
- Everolimus, Tacrolimus (FK506), Basiliximab
- Where
- 3 sites in Israel
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Function of Renal Transplant
Analysis of Foxp3 and Vimentin Expression in Renal Transplant Recipient
This observational study is designed to analyse the urinary mRNA expression of Foxp3 and Vimentin, two genes involved in tolerance and early graft dysfunction in 500 renal transplant recipients from 17 renal transplant site in…
- Trial name
- TUFEV (NCT01443013)
- Testing
- Renal Transplant
- Where
- France
- Volunteers
- 266 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Kidney Transplant, Kidney Transplant Donor
Outcomes of a Pre-operative Exercise Programme for Live Donor and Recipient Kidney Transplant Patients
The goal of this clinical trial is to learn if a pre-operative outpatient exercise programme, monitored by a smart wearable device is acceptable to live kidney donor and recipient transplant patients.
- Conditions
- Kidney Transplant, Kidney Transplant Donor, Kidney Transplant Recipient
- Trial name
- OPERATe (NCT06858098)
- Testing
- Exercise programme, Wearable smart device
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Manchester
Sexual Dysfunction
Sexual Dysfunction After Renal Transplantation
A questionnaire will be send to kidney transplant recipients to investigate characteristics of them and their sexual function, all participants in the survey are anonymous and voluntary, then analyse these characteristics.
- Trial name
- NCT05856929
- Testing
- no Intervention
- Where
- 2 sites in China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital
Sepsis and Septic Shock, Acute Respiratory Failure
Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure
Kidney transplantation is the treatment of choice for end-stage chronic kidney disease. Kidney transplantation is at the first rank of solid organ transplantation in France, with 3,376 grafts performed in 2022.
- Conditions
- Sepsis and Septic Shock, Acute Respiratory Failure, Kidney Transplant Recipients, Immunosuppressive Agents
- Trial name
- REDIS (NCT06881927)
- Testing
- Hydrocortisone Hemisuccinate: 200 mg per day., reduction of the level of immunosuppression
- Where
- France
- Volunteers
- 212 people
- Sponsor
- University Hospital, Strasbourg, France
Transplant Recipient (Kidney), Steroid-Free Maintenance Immunosuppression
Studies of Kidney Transplant Outcome
The purpose of this study is to improve outcome for kidney transplant recipients. There has not been commensurate improvement in medium and long-term outcomes. Ongoing clinical research is necessary to improve transplant outcomes.
- Conditions
- Transplant Recipient (Kidney), Steroid-Free Maintenance Immunosuppression, Post-Transplant Infections, Thymoglobulin
- Trial name
- NCT01277770
- Testing
- Steroid-Free Maintenance Immunosuppression, Infection After Kidney Transplantation, Evaluation of the DGF nomogram in Thymoglobulin
- Where
- United States
- Volunteers
- 7,500 people
- Sponsor
- University of Minnesota
Cardiac Transplantation
Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients.
The purpose of the study is to determine the extent of cyclosporine microemulsion dose reduction required to maintain stable renal function in maintenance cardiac transplant recipients, after initiation of everolimus.
- Trial name
- NCT00170794
- Testing
- Everolimus (RAD001)
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplantation, Rejection
Monitoring Concentration and Pharmacodynamic Effects of Tacrolimus in Peripheral Blood Lymphocytes of Kidney Transplant Recipients
Therapeutic drug monitoring (TDM) of immunosuppressive drugs is used to improve the immunosuppressive effect while minimizing the toxicity related to exposition to high serum levels.
- Trial name
- NCT03425071
- Where
- Brazil
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Surgical Site Reaction
The Use of the Prevena Incision Management System (PIMS) on Closed Incisions in Renal Transplant Subjects
This study is being conducted to see how safe and effective the Prevena Incision Management System "Prevena" is when placed over a renal transplantation incision. Prevena provides negative pressure (suction) wound therapy.
- Trial name
- PIMS (NCT01341444)
- Testing
- Prevena Incision Management System, Standard of Care for Surgical Incisions
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- KCI USA, Inc
Kidney Transplant Rejection
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
The purpose of this open-label, randomized, active-comparator-controlled study is to determine the efficacy and safety of frexalimab subcutaneous administrations up to 5 years compared to tacrolimus capsules in adults undergoing…
- Trial name
- FREXERA (NCT07412470)
- Testing
- Frexalimab, Tacrolimus, rabbit anti-thymocyte globulin
- Where
- 73 sites in United States, Argentina and 16 more
- Volunteers
- 526 people
- Sponsor
- Sanofi
De Novo Transplant Disease
Efficacy and Safety Study of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus(ADEQUATE)
This prospective, interventional, open label, randomized, multicenter study was designed to determine the risk/benefit ratio of a 50 % reduction of Advagraf® daily dose, 4 months after transplantation.
- Trial name
- ADEQUATE (NCT01744470)
- Testing
- Tacrolimus targeted half-dose, Tacrolimus targeted plain dose
- Where
- 16 sites in France
- Volunteers
- 286 people
- Sponsor
- University Hospital, Tours
Kidney Transplant, Liver Transplant
Letermovir for R+ Study
The purpose of this clinical trial is to find out whether a medication, called letermovir, can help prevent a virus called cytomegalovirus (CMV) in participants who receive a kidney or liver transplant and who have already been…
- Trial name
- MISP CMV (NCT07706166)
- Testing
- Letermovir
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- University of Wisconsin, Madison
Renal Transplant
Belatacept to Prevent Organ Rejection in Kidney Transplant Patients
Belatacept is an experimental medication shown in clinical trials to have immune system suppression properties in people who have had renal (e.g., kidney) transplants.
- Trial name
- BESTT (NCT00346151)
- Testing
- Belatacept, Sirolimus, Anti-thymocyte globulin
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Occurrence of Renal Dysfunction (GFR ≤ 60mL/(Min·1.73m2)) in Renal Transplant Recipients Within One Year After Kidney Transplantation
Multimodal Ultrasound in DBD Kidneys for Predicting Early Postoperative Renal Insufficiency Risk
The objective of this observational study is to investigate the multimodal ultrasound parameters of kidneys from brain-dead organ donors prior to donation, in order to construct a predictive model for assessing the risk of early…
- Trial name
- NCT07090512
- Testing
- Multimodal Ultrasound
- Where
- China
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bei Wang
Hiv, Kidney Transplant
Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients
The purpose of this proof of concept, pilot study is to determine whether the unique combination of the human immunodeficiency virus (HIV) co-receptor antagonist, Maraviroc, and the mammalian target of rapamycin (mTOR) inhibitor…
- Conditions
- Hiv, Kidney Transplant, HIV Reservoir, CCR5
- Trial name
- NCT02990312
- Testing
- Sirolimus + Maraviroc
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
HIV-infected Patient Kidney Transplant Recipient
Pharmacokinetics of Calcineurin & mTOR Inhibitors in HIV-1 Infected Kidney Transplant Recipients After Switch to BIC/FTC/TAF
Chronic kidney disease (CKD) is a critical comorbidity for patients living with HIV (PLWH), with an estimated prevalence between 2.4 and 17%, leading to end-stage renal disease 3 to 6 fold more than non-HIV population.
- Trial name
- KINETIK (NCT04993872)
- Testing
- Biktarvy Tab
- Where
- 2 sites in France
- Volunteers
- 5 people
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba